

February 14, 2023

To,
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Dear Sir / Madam,

SYMBOL: AJOONI

Sub.: Approval of Un-audited Financial Results for the quarter ended December 31, 2022.

Dear Sir,
Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the Company at their meeting held on 14th February 2023 at the Registered Office of the company have considered and approved the Un-audited Financial Results for the quarter ended December 31, 2022. In this regards, we are enclosing herewith:

1. Un-Audited Financial Results for the quarter ended December 31, 2022.
2. Limited Review Report from the auditor for the quarter ended December 31, 2022.

You are requested to kindly take the same on record.

Thanking You,
Yours Truly,
For Ajooni Biotech Limited

Jasjot Singh
Managing Director

DIN: 01937631

SWATI
VIJAN

Digitally signed by
SWATI VIJAN
Date: 2023.02.14
12:09:43 +05'30'

AJOONI BIOTECH LIMITED
CIN : L85190PB2010PLC040162

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2022 (In Lakhs)

	PARTICULARS	Quarter Ended					Year Ended (Audited)
		31.12.2022	30.09.2022	31.12.2021	Period Ended (UnAudited)	Period Ended (Unaudited)	
					31.12.2022	31.12.2021	
I	Income						
	Revenue from operations	1,062.97	1,029.14	1,928.77	3,323.18	5,352.59	7403.77
	Other income	2.13	0.34	0.66	3.25	2.39	3.81
	Total income from operations	1,065.10	1,029.48	1,929.43	3,326.43	5,354.98	7,407.58
II	Expenses						
	Cost of Material Consumed	915.72	767.05	1,721.58	2,754.82	4,626.45	6,391.49
	Change In Inventories	-42.09	55.98	19.50	(28.33)	2.79	9.84
	Employee benefit expenses	51.48	45.86	44.85	149.79	124.98	148.14
	Finance costs	12.52	13.38	7.89	35.82	43.37	54.00
	Depreciation and amortization expenses	26.45	25.32	34.39	76.71	82.19	111.07
	Payment to NSE	-					
	Other expenses	90.35	101.63	45.86	264.60	333.75	546.93
	Total expenses	1,054.43	1,009.22	1,874.07	3,253.41	5,213.53	7,261.47
III	Profit/(Loss) before exceptional items and tax	10.67	20.26	55.36	73.02	141.45	146.11
IV	Exceptional items						
V	Profit/(Loss) before tax	10.67	20.26	55.36	73.02	141.45	146.11
VI	Tax expenses						
	a) Current tax	2.77	5.27	12.76	18.99	36.777	44.76
	b) Deferred tax	2.91	0.55	1.80	4.51	4.6	3.53
	b) Mat Credit			-	-	-	
VII	Net Profit/(Loss) for the period/year	10.81	15.54	44.40	58.54	109.27	104.88
VIII	Other comprehensive income (net of tax)						
	Items that will not be reclassified to profit or loss:				-	5	(32)
	Total other comprehensive income			-	-	5	(32)
IX	Total comprehensive income for the period/year (VII+VIII)	10.81	15.54	44.40	58.54	114.20	73.16
X	Paid-up equity share capital (face value of the share shall be indicated)	1,752.27	1,000.55	1,000.55	1,752.27	1,000.55	1,000.55
XI	Other equity (excluding revaluation reserve)	2,180.36	685.41	681.91	2,180.36	681.91	637.67
XII	EPS in Rs. (Face Value of Rs.10/- each)*						
	-Basic	0.06	0.16	0.44	0.33	1.09	1.05
	-Diluted	0.06	0.16	0.44	0.33	1.09	1.05

Notes:

- The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 14.02.2023 after being reviewed by the Audit Committee.
- The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.
- Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.

For Ajooni Biotech Limited

Jasjot Singh
Managing Director
DIN:
01937631

Date: 14.02.2023

Place : Mohali

AJOONI BIOTECH LIMITED**CIN : L85190PB2010PLC040162**Statement of Assets and Liabilities
For the Year ended on 31ST DECEMBER 2022

in Rs.

PARTICULARS	31ST DEC 22	31ST MARCH 2022
I. ASSETS		
(1) Non - Current Assets		
a) Property, Plant and Equipment	6,55,23,293	6,20,52,358
b) Financial Assets		
(1) Non-Current Investments	95,90,692	70,38,909
c) Deffered Tax Asset	22,69,859	18,18,383
(2) Current Assets		
a) Inventories	6,00,81,853	5,88,17,040
b) Financial Assets		
(1) Cash & Cash Equivalent	22,73,20,415	5,73,855
(2) Short Term Loans and advances	1,88,43,539	2,14,71,815
(3) Trade Receivables	15,32,88,283	13,84,02,877
TOTAL Rs.	53,69,17,934	29,01,75,237
II EQUITY AND LIABILITIES		
(1) Equity		
a) Equity Share Capital	17,52,27,442	10,00,55,820
b) Other Equity	21,80,35,815	6,37,67,836
(2) Non-Current Liabilities		
a) Financial Liabilities		
(1) Borrowings	1,82,15,595	2,57,63,844
(3) Current Liabilities		
a) Financial Liabilities		
(1) Borrowings	5,67,35,570	2,77,40,793
(2) Trade Payables	4,89,07,152	6,79,91,141
b) Other Current Liabilities	1,78,97,841	3,79,543
c) Current tax liabilities (Net)	18,98,520	44,76,260
TOTAL Rs.	53,69,17,934	29,01,75,237

Date: 14.02.2023

Place: Mohali

For Ajooni Biotech Limited


 Jasjot Singh
 Managing Director
 DIN: 01937631

AJOONI BIOTECH LTD

"A" (1) CASH FLOW FROM OPERATING ACTIVITIES									
									73,00,996.00
	Profit/(Loss) Before Tax								
	Adjustments for:								
	Depreciation & Amortization						76,71,967.48		
	Change in reserves						-19,27,996.00		
	Interest & Finance Charges						35,82,181.00		
									93,26,152.48
									1,66,27,148.48
	Operating Profit before Working Capital Changes								
	Adjustments for:								
	Decrease/(Increase) in Receivables						-1,48,85,406		
	Decrease/(Increase) in Inventories						-12,64,813		
	Decrease/(Increase) in Loans and Other Advances						26,28,276		
	Decrease/(Increase) in Other Assets								
	Increase/(Decrease) in Trade Payables						-1,90,83,989		
	Increase/(Decrease) in Other Current Liabilities (including Provision)						1,49,40,558		-1,76,65,375
	Cash generated from operations								
									(10,38,226.50)
	Tax paid/refund								-1899741.2
	Net Cash flow from Operating activities								
									(29,37,967.70)
	(2) CASH FLOW FROM INVESTING ACTIVITIES								
	Purchase of Tangible Assets/						-1,11,42,902.00		
	(Increase)/Decrease by sale/ purchase in Non-Current Investments						-25,51,783		
	Interest Income								
									-1,36,94,684.96
	Net Cash used in Investing activities								
	(3) CASH FLOW FROM FINANCING ACTIVITIES								
	Share premium						150343244		
	Proceeds from Issue of Share Capital						7,51,71,622		
	Proceeds from/ (Repayment) of Long term Borrowings						-75,48,250		
	Increase/(Decrease) in Short Term Borrowings						2,89,94,777		
	Interest and Other Finance Costs paid						-3582181		
									24,33,79,212
	Net Cash used in financing activities								
									22,67,46,559.78
"B"	Net increase in cash & Cash Equivalents								
	Add: Cash and Cash equivalents at the Beginning of the Year								5,73,855
"C"	Cash and Cash equivalents at 31.12.2022								22,73,20,415.00

For Ajooni Biotech Limited

7701
Jasjot Singh
Managing Director
DIN: 01937631





Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

(A PEER REVIEWED FIRM)

Limited Review Report on Standalone Financial Results

To Board of Directors of M/s Ajooni Biotech Limited


We have reviewed the Standalone Un-Audited Financial Result of **M/s. Ajooni Biotech Limited** having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter ended 31ST December 2022 ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the Securities and Exchange Board of India ('SEBI') from time to time.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Harjeet Parvesh & Co.
Chartered Accountants



Date : 14.02.2023

UDIN : 23547759BGROEF1154